Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
03 juin 2021 07h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...
COVID-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-SARS-CoV-2 Activity at Low Concentrations; Clinical Trial Forthcoming
24 août 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be greater than 300 in a human lung epithelial cell lineBrilacidin’s...
Innovation Pharmaceuticals – Clinical Trial Testing of Brilacidin Against SARS-CoV-2 (COVID-19) Targeted to Commence Q4 2020
13 juil. 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned...
In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial
07 juil. 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports the latest developments related...
Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
17 juin 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
Data From Ongoing Testing at U.S. Regional Biocontainment Laboratory Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties...
Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic
11 juin 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers...
Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
26 mai 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...
Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity
19 mai 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19 WAKEFIELD, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Innovation...